What were the primary drivers of Amgen's revenue growth in the second quarter of 2002?

Amgen's revenue growth in the second quarter of 2002 was primarily driven by a substantial increase in product sales, which rose by 30% year-over-year. Key contributors included EPOGEN® and Aranesp™, with combined sales showing a 21% increase. Additionally, NEUPOGEN® and the newly launched Neulasta™ also showed strong performance, with combined sales increasing by 39%.

How has the acquisition of Immunex Corporation impacted Amgen's financial position and future outlook?

The acquisition of Immunex Corporation, completed in July 2002 (subsequent to the reporting period's end, but a significant subsequent event), is expected to be transformative for Amgen. While the results presented are primarily for Amgen standalone, the acquisition significantly expands Amgen's product portfolio, most notably with the addition of Enbrel®. The company anticipates substantial future growth driven by Enbrel® and other key products. The acquisition also involves significant integration efforts and future capital expenditures related to acquired facilities.

What is the company's liquidity and capital resource situation?

Amgen maintained a strong liquidity position, with cash and cash equivalents and marketable securities totaling $5.06 billion at June 30, 2002, a significant increase from the prior year-end. This was supported by strong cash flow from operating activities ($1.12 billion for the first six months of 2002) and strategic financing, including the issuance of convertible notes. The company also has an ongoing stock repurchase program and sufficient debt financing options to support its operations and growth initiatives.

How are Amgen's R&D and SG&A expenses trending?

Research and development (R&D) expenses increased by 12% for the quarter and 5% for the six months, primarily due to higher staff costs and clinical trial expenses supporting product development. Selling, general, and administrative (SG&A) expenses saw a more significant increase of 42% for the quarter and 34% for the six months, driven by increased marketing support for new product launches and higher staff-related costs. These increases reflect Amgen's investment in growth and new product commercialization.

AMGN 10-Q Quarterly Report Q2 FY2002 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported strong financial performance for the second quarter and first half of 2002, demonstrating significant revenue and net income growth year-over-year. Total revenues increased by 27% to $1.25 billion for the quarter and 20% to $2.26 billion for the six-month period. This growth was primarily driven by robust product sales, notably from EPOGEN® and the newer Aranesp™ and Neulasta™. Operating income also saw substantial increases, reflecting effective cost management despite rising R&D and SG&A expenses associated with new product launches and strategic initiatives. A significant event during the period was the completion of the acquisition of Immunex Corporation on July 15, 2002. While the financial results presented here are primarily for Amgen on a standalone basis prior to the full integration of Immunex, the acquisition is poised to significantly expand Amgen's product portfolio and market presence, particularly with the addition of Enbrel®. Amgen maintained a strong liquidity position, with a significant increase in cash and cash equivalents due to operating activities and strategic financing, including the issuance of convertible notes. The company also continued its aggressive stock repurchase program. Investors should note the company's forward-looking statements highlighting continued growth driven by new products, alongside ongoing strategic investments and potential challenges from competition and regulatory environments.

Key Highlights

1Total revenues increased by 27% year-over-year to $1.25 billion for the three months ended June 30, 2002, and by 20% to $2.26 billion for the six months ended June 30, 2002.
2Net income rose to $412.4 million ($0.38 per diluted share) for the quarter and $753.3 million ($0.70 per diluted share) for the six months, up from $321.9 million ($0.30 per diluted share) and $626.8 million ($0.58 per diluted share) respectively in the prior year.
3Product sales were a key driver of growth, increasing by 30% to $1.12 billion for the quarter and 22% to $2.02 billion for the six months.
4The company completed the significant acquisition of Immunex Corporation on July 15, 2002, which is expected to enhance its product portfolio and market position.
5Amgen issued $3.95 billion in aggregate face amount of 30-year, zero-coupon senior convertible notes in March 2002, generating significant proceeds and strengthening its capital structure.
6The company significantly increased its stock repurchase activity, buying back $1.31 billion of common stock in the first six months of 2002, demonstrating a commitment to shareholder value.
7Operating expenses, including R&D and SG&A, increased year-over-year due to investments in new product development and commercialization efforts, alongside higher staff-related costs.

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2002

Summary

Key Highlights

Frequently Asked Questions